drugset / Trial / NCT01847391

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

NCT01847391

Phase 1 Completed 36 enrolled Gilead Sciences
RandomizedFactorialSingle-blindTreatment

Summary

This is a phase 1, single-blind, randomized, placebo-controlled, multiple ascending dose study aimed to assess the safety, tolerability, and pharmacokinetics of GS-6615 in healthy subjects.

Timeline

Start
2013-05
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Eleclazine Small molecule 3 mg Oral
Subject Eleclazine Small molecule 6 mg Oral
Subject Eleclazine Small molecule 9 mg Oral

Indications